CPI VIGOR PACEMAKER 109-PATIENT STUDY OFFERS MODEL FOR SPEEDIER APPROVALS, FDA SAYS; PANEL RECOMMENDS APPROVAL OF VIGOR, MEDTRONIC LEGEND PLUS PACERS
This article was originally published in The Gray Sheet
Executive SummaryCardiac Pacemakers, Inc.'s small (109-patient) premarket approval application study of its Vigor DR (dual chamber) rate responsive pacer systems provides a model for future pacemaker studies, FDA said at a Circulatory System Device Panel meeting May 9 in Gaithersburg, Maryland.
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.